Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is finding
success through its ability to form subsidiaries specializing in the use of its
patented drug-delivery platform, DehydraTECH. A recent article discussing the
company reads, “DehydraTECH is a drug-delivery platform patented for
cannabidiol and all other nonpsychoactive cannabinoids, as well as THC
(tetrahydrocannabinol) and psychoactive cannabinoids. The technology is an
enabling platform that works across multiple industries, thereby providing a
large base of consumers with healthier forms of consumption than lighting up. .
. . LXRP and DehydraTECH stand out among the competition. The company has a
total of 10 patents issued with more than 50 patents pending worldwide. Few
companies within the cannabis industry have attracted the attention of Fortune
500-type corporations, and even fewer are inking deals on their own terms.
Lexaria Bioscience is one such standout.”
To view the full article, visit http://ibn.fm/sQK2K
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and quicker onset of lipophilic active molecules. Lexaria has 10
patents granted in the United States and Australia, and has filed over 50
patent applications worldwide across 10 patent families. Lexaria’s technology
provides more rapid delivery to the bloodstream, as well as important
taste-masking benefits for orally administered bioactive molecules including
cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine
and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
